GH Research PLC reported a net loss of $10.8 million for Q1 2025, or $0.19 per share. The company met its primary endpoint in the Phase 2b trial for GH001 in TRD, showing a -15.5 point placebo-adjusted MADRS reduction. The company also reported a strong cash position of $315.3 million as of March 31, 2025, following a public offering that generated $150.0 million.